Hodgkin's lymphoma therapy: past, present, and future

Rathore, Bharti; Kadin, Marshall E.

doi:10.1517/14656566.2010.515979

Cited by 36 publications

(28 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 Although IPS is the standard stratification system for survival in patients with advanced-stage disease, it is limited to selecting distinct subgroups of patients at very high risk of recurrence. 65 This result suggests that MET or MST1R positivity provides additional prognostic information, independent of IPS.…”

Section: Discussionmentioning

confidence: 82%

MET and MST1R as prognostic factors for classical Hodgkin's lymphoma

et al. 2013

View full text Add to dashboard Cite

MST1R (RON) and MET are receptor tyrosine kinase gene family members that form a noncovalent complex on the cell surface, a critical step in tumor progression. A recent study suggested a prognostic role of MET expression in Hodgkin/Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL). The purpose of this study was to examine the prognostic significance of MET and MST1R expression in cHL. The prognostic impact of MET and MST1R was examined in 100 patients with cHL (median age: 32 years) by immunohistochemistry and mRNA in situ hybridization. The median follow-up time was 95 months (interquartile range: 42-126 months). MET or MST1R protein expression was associated with high MET or MST1R mRNA expression, respectively. Thirty-eight patients (38%) expressed MET protein in HRS cell, which was associated with better overall survival (P ¼ 0.004). Twenty-six patients (26%) expressed MST1R protein, which was associated with better overall survival (P ¼ 0.022) and event-free survival (P ¼ 0.021). Multivariate analysis identified MET protein as an independent prognostic factor for overall survival and MST1R protein as an independent prognostic factor for event-free survival. Subgroup analysis according to Ann Arbor stage showed that expressions of MET and MST1R protein have prognostic impact in the advanced stage only. In particular, coexpression of MST1R and MET protein was associated with a better survival outcome than MET or MST1R expression alone or no expression. This study suggests that MET and MST1R are independent prognostic factors in classical cHL, and may allow the identification of a subgroup of cHL patients who require more intensive therapy.

show abstract

Section: Discussionmentioning

confidence: 82%

MET and MST1R as prognostic factors for classical Hodgkin's lymphoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The median number of prior therapies was 6 (range, [3][4][5][6][7][8][9][10][11][12][13][14]. There were 9 of 21 patients who were refractory to last treatment.…”

Section: Demographicsmentioning

confidence: 99%

“…1, 2). However, depending on initial stage and first-line therapy, approximately 10% to 30% of patients presenting with cHL are expected to become refractory to initial therapy or to relapse (3,4). Even at first relapse, approximately 50% of patients can be cured with high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT; ref.…”

Section: Introductionmentioning

confidence: 99%

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

Tresckow

Morschhauser

Ribrag

et al. 2015

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).Experimental Design: Patients !18 years with histopathologically confirmed initial diagnosis of cHL that had relapsed or was refractory after !1 appropriate therapies were assigned to sequential cohorts of oral daily doses of JNJ-40346527 (150, 300, 450, 600 mg every day, and 150 mg twice a day). For the doseescalation phase, the primary endpoint was to establish the recommended phase II dose. Secondary endpoints included safety, pharmacokinetics, and pharmacodynamics.Results: Twenty-one patients [(150 mg: 3; 300 mg: 5; 450 mg: 3, 600 mg: 3) every day, and 150 mg twice a day: 7] were enrolled, 10 men, median age 40 (range, 19-75) years, median number of prior systemic therapies 6 (range, 3-14).

show abstract

“…The integration of the new biologic markers evaluated in HL, that clearly driving force for an abnormal local and systemic antitumor immunity in HL, make of HL an ideal candidate for immunotherapeutic strategies (Rathore & Kadin, 2010;Younes, 2009). The pro-survival and pro-death receptors expressed by tumoral cells are currently being explored for novel treatment strategies by using a variety of naked and conjugated monoclonal antibodies.…”

Section: Body's Own Power Protection Challenges In Hlmentioning

confidence: 99%